These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9680944)

  • 1. Cutaneous toxicity following administration of dactinomycin.
    Van Gool SW; van den Oord J; Uyttebroeck A; Brock P
    Med Pediatr Oncol; 1998 Aug; 31(2):128. PubMed ID: 9680944
    [No Abstract]   [Full Text] [Related]  

  • 2. Actinomycin D, hepatic toxicity and Wilms' tumour--a mystery explained?
    Davidson A; Pritchard J
    Eur J Cancer; 1998 Jul; 34(8):1145-7. PubMed ID: 9849471
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous toxicity following the administration of dactinomycin.
    Coppes MJ; Jorgenson K; Arlette JP
    Med Pediatr Oncol; 1997 Sep; 29(3):226-7. PubMed ID: 9212851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Veno-occlusive disease of the liver in right-sided Wilms' tumours.
    Tornesello A; Piciacchia D; Mastrangelo S; Lasorella A; Mastrangelo R
    Eur J Cancer; 1998 Jul; 34(8):1220-3. PubMed ID: 9849483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatopathy-Thrombocytopenia Syndrome During Actinomycin D Treatment May Be Related to MDR1 (ABCB1) Gene Polymorphisms.
    Baskin Y; Amirfallah A; Calibasi G; Olgun N
    Am J Ther; 2016; 23(2):e594-6. PubMed ID: 24413370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic veno-occlusive disease in Wilms' tumor.
    Kullendorff CM; Békássy AN
    Eur J Pediatr Surg; 1996 Dec; 6(6):338-40. PubMed ID: 9007466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective thrombocytopenia in children with Wilms tumor: an immune-mediated effect of dactinomycin?
    Shannon A; Smith J; Nagel K; Levesque R; Warkentin T; Barr R
    Med Pediatr Oncol; 2003 Nov; 41(5):483-5. PubMed ID: 14515398
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatopathy-thrombocytopenia syndrome (HTS) after actinomycin-D therapy: report of three cases and review of the literature.
    Farruggia P; Macaluso A; Tropia S; Di Marco F; Russo D; Grigoli A; Trizzino A; D'Angelo P
    Pediatr Hematol Oncol; 2011 Apr; 28(3):237-43. PubMed ID: 21271778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH.
    Ludwig R; Weirich A; Abel U; Hofmann W; Graf N; Tournade MF
    Med Pediatr Oncol; 1999 Nov; 33(5):462-9. PubMed ID: 10531570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine. A report of the National Wilms' Tumor Study.
    Green DM; Finklestein JZ; Norkool P; D'Angio GJ
    Cancer; 1988 Jul; 62(2):270-3. PubMed ID: 2838151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Veno-occlusive disease of the liver and nephroblastoma in children (role of the vincristine-actinomycin combination?].
    Chevallier B; Treluyer JM; Devictor D; Yaiche MC; Lagardère B
    Ann Pediatr (Paris); 1988 Sep; 35(7):525-6. PubMed ID: 2460015
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune thrombocytopenia following actinomycin-D therapy.
    Hodder FS; Kempert P; McCormack S; Bennetts GA; Katz J; Cairo MS
    J Pediatr; 1985 Oct; 107(4):611-4. PubMed ID: 2995631
    [No Abstract]   [Full Text] [Related]  

  • 13. Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH.
    Marx M; Langer T; Graf N; Hausdorf G; Stöhr W; Ludwig R; Beck JD
    Med Pediatr Oncol; 2002 Jul; 39(1):18-24. PubMed ID: 12116074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in Wilms' tumor--indications and early side effects.
    Boilletot A
    Prog Clin Biol Res; 1982; 100():111-8. PubMed ID: 6292923
    [No Abstract]   [Full Text] [Related]  

  • 15. A report of an actinomycin D study group in Japan.
    Takatsu T
    Paediatr Univ Tokyo; 1970 Jan; 17():7-9. PubMed ID: 4315852
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy PE; Thomas PR; Kim T; Shochat SJ; Haase GM; Ritchey ML; Kelalis PP; D'Angio GJ
    J Clin Oncol; 1998 Jan; 16(1):237-45. PubMed ID: 9440748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selman A. Waksman Conference on Actinomycins: their potential for cancer chemotherapy. Opening remarks.
    Farber S
    Cancer Chemother Rep; 1974; 58(1):5-7. PubMed ID: 4130355
    [No Abstract]   [Full Text] [Related]  

  • 18. The interaction of actinomycin D and radiation.
    Pearson D; Deakin DP; Hendry JH; Moore JV
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):71-3. PubMed ID: 204616
    [No Abstract]   [Full Text] [Related]  

  • 19. Fatal hepatic veno-occlusive disease with fibrinolysis as the cause of death during preoperative chemotherapy for nephroblastoma.
    Culić S; de Kraker J; Kuljis D; Kuzmić I; Saraga M; Culić V; Balarin L; Primorac D
    Med Pediatr Oncol; 1998 Sep; 31(3):175-6. PubMed ID: 9722902
    [No Abstract]   [Full Text] [Related]  

  • 20. Veno-occlusive disease with multi-organ involvement following actinomycin-D.
    D'Antiga L; Baker A; Pritchard J; Pryor D; Mieli-Vergani G
    Eur J Cancer; 2001 Jun; 37(9):1141-8. PubMed ID: 11378345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.